Inhalon Biopharma
Durham, United States (US) · Health and Medical
We built this page from public sources.
Do you work at Inhalon Biopharma?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Inhalon Biopharma is a Durham, North Carolina-based clinical-stage biotechnology company developing revolutionary inhaled antibody treatments for acute respiratory infections.We are rapidly advancing programs for the treatment of multiple respiratory infections, including Respiratory Syncytial Virus (RSV), influenza, human metapneumovirus, and SARS-CoV-2.
Overview
We are rapidly advancing programs for the treatment of multiple respiratory infections, including Respiratory Syncytial Virus (RSV), influenza, human metapneumovirus, and SARS-CoV-2. Because preventative vaccine therapies for acute respiratory infections fail to fully protect people from infection, Inhalon’s breakthrough technology has the potential to address a massive unmet need by treating active infection, directly in the lung.
Our core technology, ‘muco-trapping,’ utilizes engineered antibodies to capture pathogens within the lung mucus, effectively blocking their spread and facilitating their rapid elimination. This innovative approach represents a significant advancement in respiratory care, offering a simplified ‘test-to-treat’ model for patients.
Contact Details
Durham, United States (US)
Company Type
Private Limited Company
Employees
2-10
Categories
Products
Companies teams usually look at after Inhalon Biopharma
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.